Your browser doesn't support javascript.
loading
Development, validation and long-term evaluation of a liquid chromatography-tandem mass spectrometry method for simultaneous quantification of amiodarone, desethylamiodarone and mexiletine in human plasma and serum.
Braakhuis, Martinus W A; Pistorius, Marcel C M; Postema, Pieter G; Hollak, Carolina E M; Swart, Eleonora L.
Afiliación
  • Braakhuis MWA; Department of Pharmacy and Clinical Pharmacology, University of Amsterdam, Amsterdam UMC Location AMC, Amsterdam, The Netherlands; Medicines for Society Platform, Amsterdam UMC - University of Amsterdam, Amsterdam, The Netherlands. Electronic address: m.w.a.braakhuis@amsterdamumc.nl.
  • Pistorius MCM; Medicines for Society Platform, Amsterdam UMC - University of Amsterdam, Amsterdam, The Netherlands.
  • Postema PG; Department of Clinical and Experimental Cardiology, Heart Center, Amsterdam UMC - University of Amsterdam, Amsterdam, The Netherlands.
  • Hollak CEM; Medicines for Society Platform, Amsterdam UMC - University of Amsterdam, Amsterdam, The Netherlands; Department of Endocrinology and Metabolism, Amsterdam UMC - University of Amsterdam, Amsterdam, The Netherlands.
  • Swart EL; Department of Pharmacy and Clinical Pharmacology, University of Amsterdam, Amsterdam UMC Location AMC, Amsterdam, The Netherlands; Medicines for Society Platform, Amsterdam UMC - University of Amsterdam, Amsterdam, The Netherlands.
Article en En | MEDLINE | ID: mdl-38996752
ABSTRACT
Amiodarone and mexiletine are used for ventricular arrhythmias, for which a combination therapy of both anti-arrhythmic drugs (AADs) is not uncommon. Therapeutic drug monitoring (TDM) can be beneficial for clinical guidance of therapy, especially to correctly identify adverse events. Desethylamiodarone, the active metabolite of amiodarone, accumulates over time and is associated with serious adverse events. Therefore, simultaneous TDM for amiodarone, desethylamiodarone and mexiletine is advantageous in clinical practice. The presented LC-MS/MS method was validated for selectivity, matrix effect, linearity, accuracy, precision, carry-over and stability. The method was continuously evaluated during eight months of clinical use. The method was shown to be linear within the measured range of 0.1 to 10 mg/L for each component. The matrix effect was considered negligible. No interfering responses were found for amiodarone, desethylamiodarone and the isotopic-labeled internal standards. A constant and reproducible within-run contribution of 45.3 %, originating from the system, was identified for mexiletine. The systemic contribution to the peak area of the lowest quantifiable concentration of mexiletine affected the selectivity and carry-over effect measurements. Multiple measurements showed that regression adjusted concentrations were accurate and reproducible, indicating calibration correction was applicable. Sample stability was found to be within limits for all storage conditions and freeze-thaw cycles. Furthermore, long-term method evaluation with external controls resulted in stable measurements with a percentage coefficient of variance between 1.3 % and 6.3 %. The presented practical and reliable method is applicable for clinical TDM and will allow clinical practitioners to guide drug therapy of amiodarone and mexiletine.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Espectrometría de Masas en Tándem / Amiodarona / Mexiletine Límite: Humans Idioma: En Revista: J Chromatogr B Analyt Technol Biomed Life Sci Asunto de la revista: ENGENHARIA BIOMEDICA Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Espectrometría de Masas en Tándem / Amiodarona / Mexiletine Límite: Humans Idioma: En Revista: J Chromatogr B Analyt Technol Biomed Life Sci Asunto de la revista: ENGENHARIA BIOMEDICA Año: 2024 Tipo del documento: Article Pais de publicación: Países Bajos